0001171843-19-006621.txt : 20191021 0001171843-19-006621.hdr.sgml : 20191021 20191021080054 ACCESSION NUMBER: 0001171843-19-006621 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20191021 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191021 DATE AS OF CHANGE: 20191021 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 191158784 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_101819.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2019-10-21 2019-10-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 21, 2019

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

171 Oyster Point Blvd., Suite 300

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company,indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 8.01. Other Events.

On October 21, 2019, Global Blood Therapeutics, Inc. issued a press release titled “GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor”. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
   
99.1 Press Release, dated October 21, 2019
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: October 21, 2019By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
(Principal Financial Officer)
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

GBT Announces Results of Post-hoc Analysis of Phase 3 HOPE Study Showing Improvement in Leg Ulcers in Patients with Sickle Cell Disease Treated with Voxelotor

First of Several Post-hoc Analyses Planned Using HOPE Study Clinical Data

Findings Presented in Poster Session at 13th Annual Academy for Sickle Cell and Thalassemia Conference

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced results of a post-hoc analysis of data from the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study of voxelotor, an oral, once-daily therapy in development for the treatment of sickle cell disease (SCD). Results of this exploratory analysis suggest that voxelotor resolved or reduced the severity of existing leg ulcers and decreased the incidence of new leg ulcers in patients with SCD. The findings are being presented in a poster session at the 13th Annual Academy for Sickle Cell and Thalassemia (ASCAT) Conference in London.

Leg ulcers are a painful and often debilitating chronic complication of SCD, affecting up to 25% of patients. Chronic, nonhealing leg ulcers in SCD are thought to be caused by severe anemia and intravascular hemolysis (rupture or destruction of red blood cells within blood vessel walls). Although hydroxyurea and chronic transfusions are used to treat SCD, no controlled clinical study data have demonstrated the efficacy of these therapies in the treatment of leg ulcers in patients with SCD.

“We are encouraged by the results of this analysis of an exploratory endpoint of the HOPE Study because they not only suggest potential clinical benefit of voxelotor in leg ulcers, a serious complication of SCD, but they are also consistent with our understanding of how the improvement in anemia and hemolysis with voxelotor can potentially translate to an improvement in related clinical morbidity,” said Josh Lehrer, M.D., chief medical officer of GBT. “This is the first of several post-hoc analyses of the HOPE Study that we intend to conduct.”

The randomized, placebo-controlled HOPE Study compared voxelotor (1500 mg and 900 mg daily) with placebo in patients ages 12 and older with SCD. Results, which were published in The New England Journal of Medicine, showed rapid and sustained improvements in hemoglobin levels and markers of hemolysis with voxelotor compared with placebo.

The exploratory post-hoc analysis included data from 17 patients who had at least one SCD-related leg ulcer either at the time of trial initiation (n=13) or developed one over the 24-week treatment period (n=4). Results showed the following:

  • All four patients treated with voxelotor 1500 mg had their leg ulcers resolve or improve. Three patients had their leg ulcers resolve, and one patient showed improvement from moderate to mild. Additionally, no patients receiving voxelotor 1500 mg reported new leg ulcers after starting treatment.
  • Among six patients with leg ulcers at the start of treatment with voxelotor 900 mg, three patients had their leg ulcers resolve, one patient showed improvement from moderate to mild, and two patients showed no change in ulcer severity. Additionally, two patients who did not have leg ulcers at the start of treatment developed them during the study.
  • None of the patients treated with placebo had their leg ulcers improve. Three patients in the placebo group who had leg ulcers at the start of treatment showed no change in ulcer severity, and two patients who did not have leg ulcers at the start of treatment developed them during the study.
  • Resolution of leg ulcers was associated with a hemoglobin occupancy of approximately 20% or higher, within the target range for inhibition of sickle hemoglobin polymerization.

GBT’s New Drug Application (NDA) for voxelotor is currently under Priority Review by the U.S. Food and Drug Administration (FDA), which provides for a six-month review, and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 26, 2020. The NDA for voxelotor is supported by data from the Phase 3 HOPE Study.

About Sickle Cell Disease
SCD is a lifelong inherited blood disorder caused by a genetic mutation in the beta-chain of hemoglobin, which leads to the formation of abnormal hemoglobin known as sickle hemoglobin (HbS). In its deoxygenated state, HbS has a propensity to polymerize, or bind together, forming long, rigid rods within a red blood cell (RBC). The polymer rods deform RBCs to assume a sickled shape and to become inflexible, which causes hemolytic anemia (low hemoglobin due to RBC destruction) that can lead to multi-organ damage and early death. This sickling process also causes blockage in capillaries and small blood vessels. Beginning in childhood, SCD patients typically suffer unpredictable and recurrent episodes or crises of severe pain due to blocked blood flow to organs, which often lead to psychosocial and physical disabilities.

About Voxelotor in Sickle Cell Disease
Voxelotor (previously called GBT440) is being developed as an oral, once-daily therapy for patients with SCD. Voxelotor works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, voxelotor blocks polymerization and the resultant sickling and destruction of red blood cells. With the potential to improve hemolytic anemia and oxygen delivery, GBT believes that voxelotor may potentially modify the course of SCD. In recognition of the critical need for new SCD treatments, the U.S. Food and Drug Administration (FDA) has granted voxelotor Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations for the treatment of patients with SCD. The European Medicines Agency (EMA) has included voxelotor in its Priority Medicines (PRIME) program, and the European Commission (EC) has designated voxelotor as an orphan medicinal product for the treatment of patients with SCD.

GBT is currently evaluating voxelotor in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a Phase 3 clinical study in patients age 12 and older with SCD. Additionally, voxelotor is being studied in the ongoing Phase 2a HOPE-KIDS 1 Study, an open-label, single- and multiple-dose study in pediatric patients (age 4 to 17) with SCD. The HOPE-KIDS 1 Study is assessing the safety, tolerability, pharmacokinetics and exploratory treatment effect of voxelotor.

About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about GBT’s development plans for voxelotor and the potential benefits of voxelotor for SCD patients and other statements containing the words “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding the availability of, and sufficiency of data to support, accelerated regulatory approval, the therapeutic potential and safety profile of voxelotor, including the potential to be a disease-modifying therapy for SCD, the potential for voxelotor to be approved and to become a new standard of care for treating adolescents and adults with SCD, the ability to implement and complete clinical development plans for voxelotor, the ability to generate and report data from our past, ongoing and potential future studies of voxelotor, regulatory review and actions relating to voxelotor, the potential commercial launch of voxelotor, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about GBT’s plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control including, without limitation, the risks that GBT’s clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with GBT’s clinical development plans or require additional studies or data to support further clinical investigation of GBT’s product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in GBT’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:
Stephanie Yao (investors & media)
GBT
650-741-7730
investor@gbt.com 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE JSON 7 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_101819.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_101819.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_101819.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_101819.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 1 97 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_101819.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false XML 10 f8k_101819_htm.xml IDEA: XBRL DOCUMENT 0001629137 2019-10-21 2019-10-21 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2019-10-21 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 171 Oyster Point Blvd., Suite 300 South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false ZIP 11 0001171843-19-006621-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-19-006621-xbrl.zip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�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end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3
Cover
Oct. 21, 2019
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 21, 2019
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 171 Oyster Point Blvd., Suite 300
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false